2019 Work Meeting of the National Drug Regulatory Policies and Regulations was Held in Beijing

  • 2019-07-29
From July 25 to 26, 2019, the work meeting of the national drug regulatory policies and regulations was held in Beijing. Deeply learnt the Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era, was guided by comprehensively implementing the rule of law of new concept, thinking and strategy of the General Secretary Xi Jinping, implemented the spirit of the 2019 work meeting of national drug regulation, and summarized the achievements of policies and regulations since the reform of drug regulatory agencies in 2018, planed key tasks for the next phase, and comprehensively advanced drug regulatory policies and regulations in the new era. Xu Jinghe, the member of Party Group and the Deputy Director of the National Medical Products Administration, attended the meeting and gave a speech.

The meeting stressed that, since the 18th National Congress of the Communist Party of China, Genernal Secretary Xi Jinping, gave the important indications and intructions on comprehensively strenghthening drug safety, and indicated the directions on drug regulatory policies and regulations to do a good job in a new era. At present, the rule of law work in drug supervision of China is facing a rare opportunity for development, and we shall must make a scientific judgment and accurately grasp the situations and tasks, make full use of the rule of law means to safeguard drug safety of China and safeguard the health rights and interests of the broad masses of the people.

The meeting fully recognized the achievements made in the course of national drug regulatory policies and regulations in 2018. (1) Steadily promoted the formulation and revision of the Vaccine Administration Law of the People’s Republic of China, the Pharmaceutical Administration Law of the People’s Republic of China, the Regulation on the Supervision and Administration of Medical Devices, and the Regulations on Supervision and Administration of Cosmetics; (2). deepened research on major policies for drug regulation, and established and improved a long-term mechanism for vaccine and drug regulation; (3) actively participated in the reform of regulatory agency, and promoted synergy and efficiency in optimizing regulatory functions in accordance with the law; continued to clean up administrative licensing matters in the drug sector, pushed forward the reform of “separating licenses from licenses”, cleaned up certification matters, and deepened the reform of delegating, regulating and serving medicines with effective results; (4) improved regulatory and law enforcement systems and mechanisms to make law enforcement more transparent, standardized and fair; (5) and organized and carried out the assessment of supervision of drug safety, and effectively promoted the further implementation of drug safety responsibilities.

The meeting made clear requirements on further improving drug regulatory policies and regulations in the new era. First, we shall speed up the establishment of a more complete system of laws and regulations of drug administration, constantly improve the legal system of drug safety with Chinese characteristics, with the drug administration law at its core, and consolidate the achievements of regulatory reform and innovation through legislation in a timely manner. Second, we shall accelerate the establishment of a more open mechanism for research on drug regulatory policies, and conduct in-depth fundamental, forward-looking and strategic research on major theoretical and practical issues in drug administration. Third, we shall comprehensively promote strict, standardized, fair and civilized law enforcement, improve the mechanism for drug law enforcement, step up inspection of law enforcement efforts, and better link administrative law enforcement with criminal justice. And fourth, we shall speed up the establishment of a more authoritative legal supervision system for drug administration, strengthen the efforts of supervision and inspection, assessment, examination and supervision, and strengthen guidance and supervision for law enforcement, so as to ensure the unified implementation of laws and regulations throughout the country.

The meeting pointed out that the policy and regulation was fundamental, overall and strategic. We shall, in accordance with meeting requirements of the national work on drug supervision and administration, never forget the original aspiration, keep in mind the mission, and strive to build an “iron army” spirit of policies and regulations with the firm faith, good quality, exquisite business and good manners, more consciously practice the people-centered development thought, and put the “four the mosts” of the drug safety into the whole course of construction of drug regulatory policies and regulations.

The meeting was attended by the principals from relevant departments and bureaus and units directly under the National Medical Products Administration (NMPA), all provinces (cities and districts) and staff from NMPA in charge of related business of Xinjiang Production and Construction Corps and principal from Department of Policies and Regulations, NMPA.

Source: National Medical Productions Administration